Key Insights

Highlights

Treatment Research

3 treatments under study, led by Fml Liquifilm 01 Oogdruppels Suspensie

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

2Total
Phase 4 (2)

Trial Status

Unknown2

Clinical Trials (2)

Research Network

Common Treatments

  • Fml Liquifilm 01 Oogdruppels Suspensie1
  • Hylan 015015 Mgml Oogdruppels Oplossing1
  • Retinol Palmitate1

Activity Timeline